AbCellera Biologics Inc [NASDAQ: ABCL] jumped around 0.23 points on Monday, while shares priced at $4.24 at the close of the session, up 5.74%.
AbCellera Biologics Inc stock is now 51.43% up from its year-to-date (YTD) trading value. ABCL Stock saw the intraday high of $4.4 and lowest of $3.965 per share. The company’s 52-week high price is 4.33, which means current price is +124.34% above from all time high which was touched on 07/14/25.
Compared to the average trading volume of 5.47M shares, ABCL reached a trading volume of 8057302 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about AbCellera Biologics Inc [ABCL]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABCL shares is $9.17 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABCL stock is a recommendation set at 1.25. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Leerink Partners have made an estimate for AbCellera Biologics Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on July 07, 2025. The new note on the price target was released on August 20, 2024, representing the official price target for AbCellera Biologics Inc stock. Previously, the target price had yet another raise to $9, while The Benchmark Company analysts kept a Buy rating on ABCL stock.
The Price to Book ratio for the last quarter was 1.24, with the Price to Cash per share for the same quarter was set at 2.11.
How has ABCL stock performed recently?
AbCellera Biologics Inc [ABCL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 5.21. With this latest performance, ABCL shares gained by 31.27% in over the last four-week period, additionally plugging by 39.93% over the last 6 months – not to mention a rise of 44.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABCL stock in for the last two-week period is set at 69.15, with the RSI for the last a single of trading hit 0.30, and the three-weeks RSI is set at 0.26 for AbCellera Biologics Inc [ABCL]. The present Moving Average for the last 50 days of trading for this stock 2.82, while it was recorded at 4.12 for the last single week of trading, and 2.77 for the last 200 days.
AbCellera Biologics Inc [ABCL]: Deeper insight into the fundamentals
Operating Margin for any stock indicates how profitable investing would be, and AbCellera Biologics Inc [ABCL] shares currently have an operating margin of -1395.34% and a Gross Margin at -318.94%. AbCellera Biologics Inc’s Net Margin is presently recorded at -726.23%.
Return on Equity for this stock declined to -11.96%, with Return on Assets sitting at -11.96%.
Earnings analysis for AbCellera Biologics Inc [ABCL]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABCL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbCellera Biologics Inc go to 0.83%.
Insider trade positions for AbCellera Biologics Inc [ABCL]
There are presently around $44.79%, or 58.14% of ABCL stock, in the hands of institutional investors. The top three institutional holders of ABCL stocks are: BAKER BROS. ADVISORS LP with ownership of 27.53 million shares, which is approximately 9.3556%. BAILLIE GIFFORD & CO, holding 21.91 million shares of the stock with an approximate value of $$64.86 million in ABCL stocks shares; and BAILLIE GIFFORD & CO, currently with $$31.45 million in ABCL stock with ownership which is approximately 3.611%.
